OXIS International Inc. Reports Revenue Results for the Third Quarter of 2012; Provides Earnings Guidance for the Year 2013
The company expects significant revenue growth over the next few quarters resulting in a highly profitable 2013.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.75 USD | -2.85% | +1.90% | -50.98% |
05-21 | Top Midday Decliners | MT |
05-21 | GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants | MT |
1st Jan change | Capi. | |
---|---|---|
-50.98% | 8.09M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |